Skip to content

Clinical Efficacy of Nobel Parallel CC Implants With on1 Abutment in Posterior Area Participants

Clinical Efficacy of Nobel Parallel CC Implants With on1 Abutment in Posterior Area Participants Participants: Fuming He, Jimin Jiang, Hongye Lu To Evaluate the Long-term Efficacy of on1 Abutment Produced by Nobel Biocare Manufacturer

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05399589
Enrollment
48
Registered
2022-06-01
Start date
2021-09-27
Completion date
2026-12-30
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mechanical Failure of Dental Implant Nos

Keywords

Dental implants, One abutment one time, Submerged healing, Bone Remodeling, Definitive abutment

Brief summary

1. Research background NobelBiocare manufacture put forward a new abutment called on1. This concept is based on a two-stage abutment in which the on1 abutment is placed directly on the implant during surgery and will not be disconnected since then. At present, there are very a few clinical prospective studies about clinical effect of Nobelparallel CC implant combined with on1 abutment. 2. Research objective This study will evaluate the clinical efficacy of Nobel parallel with on1 abutment compared to traditional healing cap in posterior teeth in a short term(one year) and long trem (five year) follow-up. 3. Study design and methods: Design type: prospective clinical study. Study duration: 5 years Start time: From the date of adoption of ethics. End time: 2026. Follow up examination: Panoramic images will be taken at all times to measure the marginal bone level of the implant. Clinical examination and questionnaire survey will be conducted to obtain the implant conditions and patients' satisfaction. Periodontal indexes such as keratinized gingival width, plaque index, gingival index, bleeding on probe, probing depth of peri-implant tissue will be evaluate.

Detailed description

1. Research background NobelBiocare manufacture put forward a new abutment called on1. This concept is based on a two-stage abutment in which the on1 abutment is placed directly on the implant during surgery and will not be disconnected since then. At present, there are very a few clinical prospective studies about clinical effect of Nobelparallel CC implant combined with on1 abutment. 2. Research objective This study will evaluate the clinical efficacy of Nobel parallel with on1 abutment compared to traditional healing cap in posterior teeth during a five-year follow-up. 3. Study design and methods: Design type: prospective clinical study (Non randomized clinical trial) Study duration: 5 years Start time: From the date of adoption of ethics. End time: 2026. Follow up examination: Panoramic images will be taken at all times to measure the marginal bone level of the implant. Clinical examination and questionnaire survey will be conducted to obtain the implant conditions and patients' satisfaction. Periodontal indexes such as keratinized gingival width, plaque index, gingival index, bleeding on probe, probing depth of peri-implant tissue will be evaluate. Introduction to the research scheme: Implants of Nobel Parallel CC will be implanted into the posterior teeth in the Affiliated Stomatology Hospital, Zhejiang University School of Medicine since the date of ethical adoption. Forty patients with on1 abutment will be placed with implant. Forty patients with common healing abutment will be selected with the same implants simultaneously. Panoramic images will be evaluated before surgery, immediately after surgery, immediately, 3 months, 1 year, 2 years, 3 years and 4 years after prosthesis loading. Clinical examination and questionnaire survey will be carried out 4 years after prosthesis loading to obtain periodontal indexes about peri-implant tissues. Through the evaluation of the above experimental data, on1 abutment with implant will be analyzed about the clinical efficacy.

Interventions

COMBINATION_PRODUCTuse healing cap in control group

use healing cap in control group

COMBINATION_PRODUCTuse on1 abutment instead of healing cap in test group

We will use on1 abutment instead of healing cap in a implant operation, since the former can protect the soft tissue barrier to a certain extent.

Sponsors

The Dental Hospital of Zhejiang University School of Medicine
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

The inclusion criteria were as follows: 1. At least eighteen years old without any medical contraindications, able to tolerate dental implant surgery; 2. Planned to implant with Nobel Parallel CC™ in the maxillary or mandible posterior tooth regions with single-implant-prosthesis design; 3. No requirement for further bone augmentation; 4. Sufficient space to place the abutment and future prosthesis; 5. Adhere to follow-up. The

Exclusion criteria

were as follows: 1. Uncontrolled systematic diseases (blood pressure \>180/100 mmHg, fasting blood glucose \>8.88 mmol/L, myocardial infarction in six months, cardiac function class III to IV, third- or second-degree II atrioventricular block, and double bundle branch block et al.); 2. Using drugs such as bisphosphonates within three months; 3. Heavy smoker (≥ 10 cigarettes per day), alcoholism, and drug abuse; 4. Uncontrolled periodontitis; 5. Implant site infection; 6. Pregnancy or lactation; 7. Severe malocclusion.

Design outcomes

Primary

MeasureTime frameDescription
marginal bone level (MBL)5 yearsThe MBL of the mesial and distal sites of the implants will be measured using panoramic radiograph for the two groups of each period and converted.

Countries

China

Contacts

Primary ContactFuming He, PhD
hfm@zju.edu.cn13516817697
Backup ContactJimin Jiang, Master
jjm328@zju.edu.cn18867106859

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026